Silence Therapeutics plc (NASDAQ:SLN) Short Interest Update

Silence Therapeutics plc (NASDAQ:SLN) was the target of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 560,700 shares, a decrease of 26.1% from the June 30th total of 759,200 shares. Based on an average daily volume of 157,700 shares, the short-interest ratio is presently 3.6 days.

Analyst Ratings Changes

SLN has been the subject of a number of analyst reports. Morgan Stanley upped their price objective on shares of Silence Therapeutics from $45.00 to $49.00 and gave the company an “overweight” rating in a research note on Friday, June 28th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Thursday, June 27th. Finally, Chardan Capital lifted their price objective on shares of Silence Therapeutics from $42.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 28th.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SLN. SG Americas Securities LLC acquired a new position in Silence Therapeutics in the 4th quarter valued at approximately $110,000. Legato Capital Management LLC bought a new stake in shares of Silence Therapeutics during the second quarter valued at approximately $376,000. Parkman Healthcare Partners LLC raised its stake in shares of Silence Therapeutics by 20.8% in the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,063 shares in the last quarter. Vivo Capital LLC bought a new position in Silence Therapeutics in the fourth quarter worth $8,862,000. Finally, Lynx1 Capital Management LP increased its holdings in Silence Therapeutics by 123.4% in the 1st quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock valued at $11,375,000 after buying an additional 290,855 shares during the period. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Trading Down 0.1 %

NASDAQ SLN traded down $0.03 during trading on Friday, reaching $20.99. 355,353 shares of the company’s stock were exchanged, compared to its average volume of 214,903. Silence Therapeutics has a fifty-two week low of $4.88 and a fifty-two week high of $27.72. The company’s fifty day simple moving average is $20.35 and its 200-day simple moving average is $21.40.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings results on Thursday, May 16th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.18. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. The business had revenue of $15.73 million during the quarter, compared to analysts’ expectations of $4.53 million. As a group, analysts predict that Silence Therapeutics will post -1.52 earnings per share for the current fiscal year.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.